Neoadjuvant endocrine therapy (NET) is a valuable clinical strategy in the treatment of postmenopausal, hormone-receptor-positive, HER2-negative (HR+/HER2−) breast cancer (BC) patients, especially those with strong estrogen receptor expression. This evidence concerns the gene ERBB2 and breast cancer.